To Evaluate the Efficacy and Safety of Anlotinib Combined With Allitinib in Lung Cancer
Status:
Not yet recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
This Study is To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule Combined
with Allitinib Tablets in First-line Treatment of Advanced no-squamous and No-small Cell Lung
Cancer with Epidermal Growth Factor Receptor Mutation.